ASH 2024: AML
Ziftomenib, venetoclax, and azacitadine is an close to an all-oral regimen for relapsed/refractory acute leukemias.
The benefit of alternating venetoclax regimens was shown in patients with AML and certain AML subgroups.
The confirmed complete response rate of ziftomenib with chemotherapy was high in patients with AML subtypes.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.